Key facts
- Imagene’s last known valuation is $80.5M (Jul 2025).
- It has raised $44.2M; the latest was Later Stage VC ($22.7M) in Jul 2025.
- Notable investors include Blumberg Capital, ARC Innovation Center, Aguras Pathology Investments, BeyondBio (Isarel), David Agus — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Imagene
- ·The full record, as it builds
Funding rounds
No funding rounds for Imagene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Imagene
Developer of AI-based oncology diagnostics software designed for accelerating biomarker detection and supporting precision cancer treatment. The company's software applies deep learning algorithms to analyze biopsy tissue images, identify clinically relevant biomarkers, and support translational research and drug development, enabling healthcare providers and researchers to reduce diagnostic turnaround times and enhance treatment personalization.
- Sector
- Healthcare
- HQ
- Miami, FL, United States
- Founded
- 2020
- Employees
- 40
- Website
- imagene-ai.com/
- Ownership
- Privately Held (backing)
Imagene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Imagene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Imagene in its N-PORT filings yet. We sweep new filings monthly.